• Conditions and diseases

  • Blood and immune system •
  • Cancer •
  • Cardiovascular •
  • Central nervous system •
  • Digestive system •
  • Ear and nose •
  • Endocrine, nutritional and metabolic •
  • Eye •
  • Gynaecology, pregnancy and birth •
  • Infectious diseases •
  • Injuries, accidents and wounds •
  • Mental health and behavioural conditions •
  • Mouth and dental •
  • Musculoskeletal •
  • Respiratory •
  • Skin •
  • Urogenital

• Public health

  • Accidents and injuries •
  • Alcohol •
  • Behaviour change •
  • Cancer •
  • Cardiovascular disease •
  • Child health •
  • Child social care •
  • Chronic illness •
  • Diabetes •
  • Drugs •
  • Environmental health •
  • Infectious diseases •
  • Maternal health •
  • Mental health •
  • Non-communicable diseases •
  • Obesity and diet •
  • Occupational health •
  • Older people •
  • Physical activity •
  • Sexual health •
  • Smoking and tobacco •
  • Transport •
  • Vaccine preventable diseases •
  • Working with and involving communities

• Treatments, Procedures and Devices

  • Bones and joint surgery •
  • Cardiovascular surgery •
  • Cardiovascular system drug treatments •
  • Clinical devices •
  • Diagnostic imaging •
  • Diagnostic procedures •
  • Digestive tract and other abdominal organs surgery •
  • Drug treatments •
  • Endocrine system and breast surgery •
  • Eye surgery •
  • Nervous system surgery •
  • Radiotherapy •
  • Screening •
  • Surgical procedures •
  • Therapeutic procedures •
  • Tissue and organ donation •
  • Urogenital surgery

• Guidance by type

  • Clinical Guidelines •
  • Technology appraisals •
  • Public health guidance •
  • Diagnostics guidance •
  • Interventional procedures guidance •
  • Medical technologies guidance •
  • Cancer service guidance •
  • Quality standards

• Guidance by date

  • View the guidance by date published

About NICE guidance Close

Navigation

• NICE guidance

• Find guidance
• NICE Pathways
• Latest guidance
• Guidance by type
• Guidance in development
• How guidance is produced
• NICE guidance research recommendations
• Guidance for patients and public
• Other publications
• Patient safety solutions pilot
• Quality standards

TA142 Anaemia (cancer-treatment induced) - erythropoietin (alpha and beta) and darbepoetin: costing statement

A costing statement has been produced by NICE to provide an implementation tool to estimate the financial impact to the NHS of implementing the technology appraisal TA142, epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia.

The costing statement focuses on the financial impact of the key factors in this technical appraisal for England. The report has been prepared in consultation with the technical leads and has been approved for publication by the Institute. It should be noted that the cost and activity assessments in the report are estimates based on a number of assumptions. These assessments provide an indication of the likely impact of the principal recommendations and are not absolute figures.

The Institute would welcome feedback from users to inform the development of future costing tools. Please email your comments to costing@nice.org.uk

TA142 Anaemia (cancer-treatment induced) - erythropoietin (alpha and beta) and darbepoetin: costing statement 28 May 2008 (37.49 Kb 10 sec)

Adobe Acrobat reader required.

This page was last updated: 30 March 2010